DDAVP Nasal Spray
Superpotent Drug
Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.
992 FDA drug recalls with this cause, newest first.
These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.
Superpotent Drug
Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.
SUBPOTENT DRUG
Chemical Contamination and Subpotent Drug: Product tested to contain methanol as well as below the labeled claim for ethanol content.
Chemical Contamination and Subpotent Drug: Product tested to contain methanol as well as below the labeled claim for ethanol content.
Chemical Contamination and Subpotent Drug: Product tested to contain methanol as well as below the labeled claim for ethanol content.
SUBPOTENT DRUG: Products failed assay results at the 12 and 24 month timepoints.
SUBPOTENT DRUG: Products failed assay results at the 12 and 24 month timepoints.
Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint.
Superpotent Drug: The beginning portion of the batch appears to be approximately 25% superpotent for active ingredient Meradimate.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
Subpotent Drug: active ingredient ethanol tested below label claim and there is presence of undeclared isopropyl alcohol.
Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.
Subpotent Drug: Out of specification for assay at the 9-month interval for Nystatin Cream, USP.
Super-potent Drug: This recall has been initiated due to the elevated presence of minoxidil and biotin.
Superpotent Drug: Active Ingredient Octisalate found at 15% above label claim.
Subpotent Drug: Product was found to be subpotent. Product also has high pH levels
Subpotent drug - Product did not contain drug.
Superpotent Drug.
Superpotent Drug.
Superpotent Drug.
Superpotent Drug: The active ingredient, avobenzone, is used at 5% which is higher than the allowable 3% in the sunscreen formula per FDA sunscreen regulations.
Subpotent Drug: low out of specification (OOS) test result observed in long term stability study.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.